Deloron P, Le Bras J, Savel J, Coulaud J P
Am J Trop Med Hyg. 1987 Jul;37(1):22-6. doi: 10.4269/ajtmh.1987.37.22.
Plasmodium falciparum polypeptide Pf155 is one of the main candidates for a vaccine against asexual blood stages of P. falciparum. Antibodies against Pf155 can be detected by a cell-ELISA technique with glutaraldehyde-fixed and air dried P. falciparum-infected erythrocytes as antigen. Using this assay, we measured the level of antibodies in sera from 230 subjects with various degrees of past exposure to P. falciparum. Significant levels of antibodies (OD492 greater than 0.5) were detected in 41/50 sera from Central African adults and in 34/50 sera from West African adults. All sera from 50 European adults suffering primary malarial attack and 28/30 sera from West African children (10 to 12 years old) were negative. Intermediate results were obtained with 50 sera from West African adults living in France for greater than or equal to 2 years (12 positive). Mean OD values of the sera of these five groups of subjects varied in the same direction as the positivity rates. These preliminary results suggest that the level of anti-Pf155 antibodies as detected by cell-ELISA might provide an assessment of protective immunity against P. falciparum which could complement clinical or epidemiological criteria.
恶性疟原虫多肽Pf155是抗恶性疟原虫无性血液期疫苗的主要候选物之一。抗Pf155抗体可用戊二醛固定并经空气干燥的恶性疟原虫感染红细胞作为抗原，通过细胞酶联免疫吸附测定（cell-ELISA）技术检测。利用该检测方法，我们测定了230名过去不同程度接触过恶性疟原虫的受试者血清中的抗体水平。在来自中非成年人的50份血清中有41份以及来自西非成年人的50份血清中有34份检测到显著水平的抗体（OD492大于0.5）。所有50名遭受初次疟疾发作的欧洲成年人的血清以及30份来自西非儿童（10至12岁）的血清中有28份均为阴性。在法国居住≥2年的50名西非成年人的血清中得到了中等结果（12份阳性）。这五组受试者血清的平均OD值与阳性率的变化方向相同。这些初步结果表明，通过细胞酶联免疫吸附测定检测到的抗Pf155抗体水平可能为评估针对恶性疟原虫的保护性免疫提供一种补充临床或流行病学标准的方法。
